Raymond James Financial Inc. Takes $19.08 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,112,275 shares of the biotechnology company’s stock, valued at approximately $19,076,000. Raymond James Financial Inc. owned 0.47% of ADMA Biologics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics during the 4th quarter worth about $35,000. Vision Financial Markets LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter worth approximately $51,000. AlphaQuest LLC purchased a new stake in ADMA Biologics in the fourth quarter valued at approximately $84,000. Finally, CIBC Private Wealth Group LLC raised its stake in ADMA Biologics by 137.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 2,954 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Up 0.4 %

Shares of ADMA Biologics stock opened at $21.31 on Friday. The company has a fifty day moving average price of $18.26 and a 200 day moving average price of $18.22. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $6.19 and a twelve month high of $23.64. The stock has a market cap of $5.04 billion, a price-to-earnings ratio of 76.11 and a beta of 0.53.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.